Cereblon ligands and bifunctional compounds comprising the same
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
a technology of ligands and e3 ligases, applied in the field ofimide-based compounds, can solve the problems of difficult development of ligands of e3 ligases, difficult targeting of protein-protein interactions using small molecules, and encouraging the effect of brd4 inhibition
Inactive Publication Date: 2018-08-02
ARVINAS OPERATIONS INC
View PDF3 Cites 84 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Benefits of technology
[0013]The present disclosure describes bifunctional compounds which function to recruit endogenous proteins to an E3 Ubiquitin Ligase for degradation, and methods of using the same. In particular, the present disclosure provides bifunctional or proteolysis targeting chimeric (PROTAC) compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and / or otherwise inhibited by the bifunctional compounds as described herein. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation / inhibition of targeted polypeptides from virtually any protein class or family. In addition, the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., multiple myeloma.
Problems solved by technology
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.
The development of ligands of E3 ligases has proven challenging, in part due to the fact that they must disrupt protein-protein interactions.
Thus, despite the rapid progress of BRD4 inhibitors, the effect of BRD4 inhibition has been encouraging, but less than ideal, as the effect is mostly cytostatic and requires relatively high concentration of inhibitors.
However, non-specific effects, and the inability to target and modulate certain classes of proteins altogether, such as transcription factors, remain as obstacles to the development of effective anti-cancer agents.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
chemical structure
aaaaa
aaaaa
chemical structural unit
aaaaa
aaaaa
structure
aaaaa
aaaaa
Login to view more
Abstract
The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present disclosure claims priority to U.S. Provisional Application No. 62 / 452,972, filed 31 Jan. 2017, which is incorporated herein by reference in its entirety.INCORPORATION BY REFERENCE[0002]U.S. patent application Ser. No. 15 / 230,354, filed on Aug. 5, 2016, published as U.S. Patent Application Publication No. 2017 / 0065719; and U.S. patent application Ser. No. 15 / 801,243, filed on 1 Nov. 2017; and U.S. patent application Ser. No. 15 / 206,497 filed 11 Jul. 2016; and U.S. patent application Ser. No. 15 / 209,648 filed 13 Jul. 2016; and U.S. patent application Ser. No. 15 / 730,728, filed on Oct. 11, 2017; U.S. patent application Ser. No. 15 / 829,541, filed on Dec. 1, 2017; U.S. patent application Ser. No. 15 / 881,318, filed on Jan. 26, 2018; and U.S. patent application Ser. No. 14 / 686,640, filed on Apr. 14, 2015, published as U.S. Patent Application Publication No. 2015 / 0291562; and U.S. patent application Ser. No. 14 / 792,414, filed on Jul. ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more
Patent Type & Authority Applications(United States)